tallózása szerző szerint "Szarvas, Tibor"

1-20 / 20

A felső húgyúti urothel sejtes tumorok kezelése - hasonlóságok és különbségek a húgyhólyag urotheliális tumoraival

Kubik, András; Szarvas, Tibor; Módos, Orsolya; Keresztes Dávid; Horváth, András; Nyirády, Péter (2017)
Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data

Reis H; Krafft U; Niedworok C; Módos, Orsolya; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirády, Péter; Szarvas, Tibor (2018)

Urachal cancer (UrC) is a rare but aggressive cancer. Due to overlapping histomorphology, discrimination of urachal from primary bladder adenocarcinomas (PBAC) and adenocarcinomas secondarily involving the bladder (particularly ...
Circulating and tissue expression levels of YKL-40 in renal cell cancer

Vom Dorp F; Tschirdewahn S; Niedworok C; Reis H; Krause H; Kempkensteffen C; Busch J; Kramer G; Shariat SF; Nyirády, Péter; Rubben H; Szarvas, Tibor (2016)

PURPOSE: Blood levels of YKL-40 are elevated in various malignancies and other inflammatory diseases. Moreover, higher YKL-40 levels, have consequently been shown to correlate with poor prognosis in several cancers. The ...
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer

Szarvas, Tibor; Sevcenco, S; Módos, Orsolya; Keresztes, Dávid; Nyirády, Péter; Kubik, András; Romics, Miklós; Kovalszky, Ilona; Reis, H; Hadaschik, B; Shariat, SF; Kramer, G (2018)

OBJECTIVES: Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to ...
Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases

Szarvas, Tibor; Módos, Orsolya; Niedworok C; Reis H; Szendrői, Attila; Szász, Attila Marcell; Nyirády, Péter (2016)

BACKGROUND AND OBJECTIVES: Urachal carcinoma (UrC) is a rare and poorly investigated disease. Our current knowledge is mainly based on single-institutional studies. Despite growing interest in UrC, the included case numbers ...
Clinical Sequencing-guided Therapy of Urachal Carcinoma: New Perspective for a Rare Cancer

Nyirady, Péter; Niedworok, C; Reis, H; Szarvas, Tibor (2016)
Current State of ERG as Biomarker in Prostatic Adenocarcinoma.

Ács, Balázs; Szarvas, Tibor; Szekely N; Nyirády, Péter; Szász, Attila Marcell (2015)

In this review we briefly discuss the possible biomarkers of prostate cancer among them we focus and analyze the relevance of TMPRSS2-ERG fusion gene in line with ERG expression in the diagnosis of prostate cancer. Starting ...
Detection of bladder cancer from the urine using fluorescence in situ hybridization technique

Riesz, Péter; Lotz, Gábor; Páska, Csilla; Szendrői, Attila; Majoros, Attila; Németh, Zsuzsanna; Törzsök, Péter; Szarvas, Tibor; Kovalszky, Ilona; Schaff, Zsuzsa; Romics, Imre; Kiss, András (2007)

The authors report on their first experiences with the UroVysion fluorescence in situ hybridization (FISH) kit developed for the detection of bladder cancer. This new non-invasive diagnostic application of the FISH technique ...
Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma

Droop Johanna; Szarvas, Tibor; Schulz Wolgang A; Niedworok Christian; Niegisch Günter; Scheckenbach Kathrin; Hoffmann Michéle J (2017)

Many long noncoding RNAs (lncRNAs) are deregulated in cancer and contribute to oncogenesis. In urothelial carcinoma (UC), several lncRNAs have been reported to be overexpressed and proposed as biomarkers. As most reports ...
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.

Szarvas, Tibor; Reis H; Kramer G; Shariat SF; Vom Dorp F; Tschirdewahn S; Schmid KW; Kovalszky, Ilona; Rubben H (2014)

In this study, we assessed the changes and prognostic relevance of syndecan-1 (SDC1) tissue and serum levels in bladder cancer (BC). SDC1 levels were analyzed in 213 samples (119 paraffin-embedded and 79 serum samples of ...
MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer

Szarvas, Tibor; Sevcenco, S; Módos, Orsolya; Keresztes, Dávid; Nyirády, Péter; Csizmarik, Anita; Ristl, R; Puhr, M; Hoffmann, MJ; Niedworok, C; Hadaschik, B; Maj-Hes, A; Shariat, SF; Kramer, G (2018)

PURPOSE: To assess the predictive value of pre-chemotherapy MMP-7, sFas, FasL serum levels as well as their changes during therapy. PATIENTS AND METHODS: Serum levels of MMP-7, Fas and FasL were determined by ELISA in 96 ...
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance

Módos, Orsolya; Reis H; Niedworok C; Rubben H; Szendrői, Attila; Szász, Attila; Tímár, József; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollosi P; Nyirády, Péter; Szarvas, Tibor (2016)

PURPOSE: Targeted therapy represents an attractive alternative for rare tumors such as urachal carcinoma (UrC). The aim of this study was to assess the mutations of the most commonly affected 5 genes in the targetable ...
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas

Reis, H; van der Vos, KE; Niedworok, C; Herold, T; Módos, Orsolya; Szendrői, Attila; Hager, T; Ingenwerth, M; Vis, DJ; Behrendt, MA; de Jong, J; van der Heijden, MS; Peyronnet, B; Mathieu, R; Wiesweg, M; Ablat, J; Okon, K; Tolkach, Y; Keresztes, D; Nagy, N; Bremmer, F; Gaisa, NT; Chlosta, P; Kriegsmann, J; Kovalszky, Ilona; Timár, József; Kristiansen, G; Radzun, HJ; Knuchel, R; Schuler, M; Black, P; Rubben, H; Hadaschik, B; Schmid, KW; van Rhijn, BWG; Nyirády, Péter; Szarvas, Tibor (2018)

Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospective clinical studies can hardly ...
Response to: Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma

Reis, H; Niedworok, C; Szarvas, Tibor (2017)
Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival

Niedworok C; Tschirdewahn S; Reis H; Lehmann N; Szűcs, Miklós; Nyirády, Péter; Romics, Imre; Rubben H; Szarvas, Tibor (2017)

Better prognostication of clinically localized prostate cancer (PCA) is urgently needed. Former studies using different study end-points provided controversial results regarding the prognostic value of serum chromogranin ...
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.

Szarvas, Tibor; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirády, Péter; Schmid KW; Rubben H; Kovalszky, Ilona (2016)

BACKGROUND: PSA-screening detects many cases of clinically non-aggressive prostate cancer (PC) leading to significant overtreatment. Therefore, pre-operatively available prognostic biomarkers are needed to help therapy ...
Urachal cancer - current concepts of a rare cancer

Reis, H; Szarvas, Tibor (2018)

Urachal cancer is arare but aggressive disease. In addition to the non-glandular tumors, non-cystic urachal adenocarcinomas are nowadays distinguished from the primary cystic variant. (Immunohistochemical) markers are only ...
Urachal carcinoma of the bladder - impact of clinical and immunohistochemical parameters on prognosis

Niedworok C; Panitz M; Szarvas, Tibor; Reis H; Reis AC; Szendrői, Attila; Nyirády, Péter; Szász, Attila Marcell; Módos, Orsolya; Ruebben H; Vom Dorp F (2016)

PURPOSE: Urachal carcinoma of the bladder (UrC) is a rare malignancy. Its histological phenotype is similar to that of primary bladder adenocarcinomas and colorectal adenocarcinomas. The aim of this study was to explore ...
Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.

Niedworok C; Vom Dorp F; Tschirdewahn S; Rubben H; Reis H; Szűcs, Miklós; Szarvas, Tibor (2016)

PURPOSE: Despite encouraging results in other cancers, in renal cell cancer, no consensus exists regarding the diagnostic and prognostic relevance of MMP-7. The aim of this study was to assess the diagnostic and prognostic ...
Why are upper tract urothelial carcinoma two different diseases?

Szarvas, Tibor; Módos, Orsolya; Horváth, András; Nyirády, Péter (2016)

1-20 / 20

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban

Hozzáférésem

Bejelentkezés

tallózása szerző szerint "Szarvas, Tibor"

DSpace/Manakin Repository

tallózása szerző szerint "Szarvas, Tibor"

Keresés

Tallózás

Teljes repozitórumban

Hozzáférésem